Welcome to our dedicated page for MYRIAD GENETICS SEC filings (Ticker: MYGN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Myriad Genetics Inc. filings document the regulatory record of a molecular diagnostics and precision medicine company. Recent Form 8-K reports furnish quarterly and annual financial results, preliminary revenue and test-volume information, guidance, and product-related operating updates tied to Cancer Care Continuum, Prenatal Health, Mental Health, Precise MRD, and MyChoice CDx.
The company's proxy materials cover board matters, executive compensation, equity awards, and annual meeting governance. Other current reports document officer transitions, compensatory arrangements, and amendments to previously furnished earnings materials, providing formal disclosure of governance changes and financial-reporting corrections.
State Street Corporation filed a Schedule 13G reporting a passive ownership stake in Myriad Genetics, Inc. common stock as of 12/31/2025. State Street reports beneficial ownership of 5,966,567 shares, representing 6.4% of Myriad Genetics’ outstanding common stock.
The filing shows State Street has shared voting power over 5,683,556 shares and shared dispositive power over 5,966,567 shares, with no sole voting or dispositive power. State Street certifies the shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Myriad Genetics.
Myriad Genetics reported an equity award to its Chief Financial Officer, Benjamin Richard Wheeler. On February 2, 2026, he acquired 4,994 shares of common stock at $0 per share, linked to previously granted performance-based restricted stock units (PSUs). These PSUs were originally granted on March 15, 2023, and the Compensation and Human Capital Committee set the final award amount based on performance metrics. Each PSU converts into one share of common stock and will vest on March 15, 2026. After this transaction, Wheeler beneficially owned 97,624 shares directly.
Myriad Genetics Chief Operating Officer Mark Verratti reported an award of common stock tied to earlier performance-based restricted stock units. On February 2, 2026, he acquired 32,810 shares of common stock at $0 per share, following certification of performance goals. After this award, he beneficially owned 414,636 shares directly. The underlying performance-based units were originally granted on March 15, 2023 and are scheduled to vest on March 15, 2026, with each unit representing one share of common stock.
Myriad Genetics reported that its Chief Scientific Officer, Dale Muzzey, received an award of 23,697 shares of common stock on February 2, 2026, at a price of $0 per share, increasing his directly held stake to 193,878 shares.
The shares relate to performance-based restricted stock units initially granted on March 15, 2023. The board’s Compensation and Human Capital Committee determined the final award amount based on pre-set performance metrics, and each unit will convert into one share of common stock vesting on March 15, 2026.
Myriad Genetics Chief Technology Officer Kevin Richard Haas reported an acquisition of 23,697 shares of common stock of the company on February 2, 2026 at a price of $0 per share. These shares relate to performance-based restricted stock units (PSUs) that were initially granted on March 15, 2023, with the final award amount determined by the board’s Compensation and Human Capital Committee based on preset performance metrics.
Each PSU represents a right to receive one share of Myriad Genetics common stock and is scheduled to vest on March 15, 2026. After this award, Haas beneficially owns 202,332 shares of Myriad Genetics common stock held directly.
Myriad Genetics Inc. has a new significant shareholder disclosure from Glenview Capital Management and its CEO Larry Robbins. As of January 12, 2026, they may be deemed to beneficially own 4,941,058 shares of Myriad Genetics common stock, representing approximately 5.3% of the shares outstanding.
The position is held across three Glenview-managed vehicles: 1,886,965 shares for Glenview Capital Master Fund, 2,791,657 shares for Glenview Offshore Opportunity Master Fund, and 262,436 shares for Glenview Healthcare Master Fund. Glenview and Robbins report shared voting and dispositive power over all 4,941,058 shares, with no sole voting or dispositive power. They also certify that the shares were not acquired to change or influence control of Myriad Genetics.
Myriad Genetics, Inc. reported preliminary operating trends for 2025 and introduced financial guidance for full year 2026. In a new press release, the company outlined early revenue figures for the quarter and year ended December 31, 2025 and shared its initial outlook for 2026.
For 2025, Myriad expects total test volumes of approximately 1.5 million, a 1% year-over-year increase. This reflects about 7% growth in hereditary cancer testing and 6% growth in mental health testing, partially offset by roughly a 4% decline in prenatal health testing. All financial figures are described as preliminary and remain subject to normal year-end accounting procedures and external audit, and the company includes standard cautionary language regarding forward-looking statements.
Myriad Genetics reported an insider equity event involving its President and CEO, Samraat S. Raha, who is also a director. On December 11, 2025, 29,634 shares of common stock were withheld by the company to satisfy tax withholding obligations arising from the vesting of previously granted restricted stock units, as indicated by transaction code F. The shares were valued using the closing price of Myriad common stock on that date, shown as $7.3 per share. After this tax withholding, Raha beneficially owned 453,104 shares of Myriad common stock in direct ownership. This reflects routine equity compensation and related tax settlement activity.
Myriad Genetics (MYGN) filed a Form 4/Exit noting a leadership change. The filing states that, effective on November 3, 2025, the reporting person no longer serves as EVP, Strategy & Transformation and therefore is no longer subject to Section 16 reporting.
The report lists 127,726 shares of common stock beneficially owned directly following the reported event. The form was filed by one reporting person.
Myriad Genetics reported Q3 2025 results showing steady operations but ongoing losses. Revenue was $205.7 million versus $213.3 million a year ago, with gross profit of $143.8 million and an operating loss of $23.3 million. Net loss for the quarter was $27.4 million, or $0.29 per share.
Segment trends were mixed: Hereditary Cancer revenue rose to $93.0 million, Prenatal to $44.5 million, while Pharmacogenomics fell to $38.7 million, reflecting lower average revenue per test and payer coverage changes. Year‑to‑date, the company recorded $316.7 million of goodwill and intangible impairments, driving a YTD net loss of $358.0 million and reducing intangible balances.
Liquidity strengthened with cash and equivalents of $145.4 million. Long‑term debt increased to $119.5 million after a new $125.0 million secured term loan maturing in 2030 at an interest rate of about 10.8%. The facility includes monthly trailing 12‑month revenue covenants beginning at $615.0 million as of December 31, 2025. Net cash used in operations was $8.8 million year‑to‑date.